Marlborough-based Advanced Cell Technology Inc. has received FDA clearance to start a clinical trial for a new treatment for macular degeneration.
The treatment uses cells derived from human embryonic stem cells to treat Dry Age-Related Macular Degeneration, which can affect the vision of people over 60. ACT said there are currently no treatments available for the condition, which afflicts 10 to 15 million Americans.
The trial will enroll 12 patients and will test the safety and tolerability of the treatment. ACT said the treatment has been successful in studies using rats as models.
ACT announced last week that it has secured a $25 million funding commitment through a stock purchase agreement with a subsidiary of Socius Capital Group.
